Jayne Christopher J, Heard Michael J, Zubair Sarah, Johnson Dustie L
Greater Houston Urogyn.
Department of Ob/Gyn, St Joseph Medical Center, The Heard Institute.
Int J Womens Health. 2017 Apr 10;9:171-178. doi: 10.2147/IJWH.S125356. eCollection 2017.
The objective of the authors is to highlight the historical complexities for the diagnosis and treatment of hypoactive sexual desire disorder (HSDD) with a focus on Flibanserin. A systematic review of the medical literature published in PubMed using the search terms HSDD and Flibanserin was conducted. Each author reviewed the results of the systematic review for articles to include in this study. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity causing marked distress or interpersonal difficulty that is not better accounted for by another diagnosis. Until 2015, only homeopathic products and off-label use of prescription medications were medical treatment options for women with HSDD. Flibanserin, approved by the US Food and Drug Administration (FDA) in 2015, is the first to target female HSDD in premenopausal women. Flibanserin is a centrally acting nonhormonal oral medication taken once daily that affects serotonin, dopamine and norepinephrine levels, the key neurotransmitters in the biology of desire. Understanding prescribing guidelines and awareness of black box warnings is paramount for prescribers. Adherence to proper oversight will ensure Flibanserin can fulfil an unmet need for an FDA approved prescription medication for the treatment of HSDD in premenopausal women.
作者的目的是强调性欲减退障碍（HSDD）诊断和治疗方面的历史复杂性，重点关注氟班色林。使用搜索词HSDD和氟班色林对发表在PubMed上的医学文献进行了系统综述。每位作者都对系统综述的结果进行了审查，以确定纳入本研究的文章。HSDD被定义为持续性或复发性的性幻想及性活动欲望缺乏或缺失，导致明显痛苦或人际困难，且不能用其他诊断更好地解释。直到2015年，对于患有HSDD的女性，医疗治疗选择仅为顺势疗法产品和处方药的非标签使用。氟班色林于2015年获得美国食品药品监督管理局（FDA）批准，是首个针对绝经前女性HSDD的药物。氟班色林是一种中枢作用的非激素口服药物，每日服用一次，会影响血清素、多巴胺和去甲肾上腺素水平，这些是欲望生物学中的关键神经递质。对于开处方者来说，了解处方指南和认识黑框警告至关重要。坚持适当的监督将确保氟班色林能够满足绝经前女性治疗HSDD的FDA批准处方药这一未满足的需求。
